“…Many therapeutic proteins and enzymes are N-glycosylated. The level of N-glycosylation and the structure of their N-glycans can directly affect their solubility, stability, safety, function, efficacy, delivery, pharmacokinetics, immunogenicity, and dose frequency [ 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. Therefore, N-glycosylation is a critical quality attribute (CQA) of glycoprotein therapeutics considered by regulatory authorities [ 3 , 5 , 10 ].…”